Small Pharma Inc. (CVE:DMT – Get Free Report) fell 6.3% during mid-day trading on Tuesday . The company traded as low as C$0.15 and last traded at C$0.15. 1,890,765 shares traded hands during mid-day trading, an increase of 538% from the average session volume of 296,159 shares. The stock had previously closed at C$0.16.
Small Pharma Stock Performance
The company has a market capitalization of C$50.37 million, a price-to-earnings ratio of -2.14 and a beta of 0.86. The stock has a 50 day simple moving average of C$0.15 and a 200 day simple moving average of C$0.15. The company has a quick ratio of 6.28, a current ratio of 2.63 and a debt-to-equity ratio of 5.95.
About Small Pharma
Small Pharma Inc, a biotechnology company, focuses on developing short-duration psychedelic-assisted therapies for the treatment of mental health conditions. Its clinical program is based on N,N, dimethyltryptamine, a naturally occurring psychoactive molecule. The company's product includes SPL026, which is in clinical Phase IIa for the treatment of major depressive disorder; and SPL028, an injectable formulation of deuterated DMT, which is in Phase 1 clinical trial, as well as SPL801B, an oral dosage.
Further Reading
- Five stocks we like better than Small Pharma
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Super Micro Computer Soars 28%: Is It Really Out of the Woods?
- Top Stocks Investing in 5G Technology
- Traders Are Flocking Back to Oil: What’s Fueling the Optimism
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- 3 Hot Stock Trends to Ride Into 2025
Receive News & Ratings for Small Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Small Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
